Status:
UNKNOWN
Degarelix Before Radical Prostatectomy
Lead Sponsor:
University of Cambridge
Conditions:
Prostate Cancer
Eligibility:
MALE
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
The biological effects of castration on prostate cancers will be studies by administration of degarelix prior to radical prostatectomy. The effects will be studied by analysis of gene expression and ...
Eligibility Criteria
Inclusion
- Intermediate/high risk prostate cancer
- Patient eligible for and wanting surgery
Exclusion
- Inability to consent
- Previous thromboembolism/arrhythmias
- contraindication to degarelix or surgery
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01852864
Start Date
July 1 2011
End Date
December 1 2015
Last Update
December 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cambridge University Hopital NHS Trust
Cambridge, Cambridgeshire, United Kingdom, CB20QQ